What's in Memorial Sloan Kettering Cancer Center's pipeline?

Memorial Sloan Kettering Cancer Center has 45 drugs in our index: 15 marketed, 0 filed, 14 in Phase 3, 3 in Phase 2, 13 in Phase 1.

Which companies overlap with Memorial Sloan Kettering Cancer Center's portfolio?

Top competitors by shared drug class: Hospices Civils de Lyon, Assistance Publique - Hôpitaux de Paris, Jiangsu HengRui Medicine Co., Ltd., Merck Sharp & Dohme LLC, Sun Yat-sen University.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/memorial-sloan-kettering-cancer-center.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Memorial Sloan Kettering Cancer Center — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Memorial Sloan Kettering Cancer Center pipeline: 15 marketed, 0 filed, 14 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

15 marketed 0 filed 14 Phase 3 3 Phase 2 13 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
therapeutic testosterone	therapeutic testosterone	marketed	Androgen replacement therapy	Androgen receptor (AR)	Endocrinology / Oncology
Trastuzumab deruxtecan-nxki	Trastuzumab deruxtecan-nxki	marketed	HER2-targeted antibody-drug conjugate (ADC)	HER2 (human epidermal growth factor receptor 2)	Oncology
Pembrolizuma	Pembrolizuma	marketed		Programmed cell death protein 1	Oncology
Daratumumab Hyaluronidase-fihj	Daratumumab Hyaluronidase-fihj	marketed	CD38-targeting monoclonal antibody	CD38	Oncology
Vancomycin and Gentamicin	Vancomycin and Gentamicin	marketed	Antibiotic combination (glycopeptide + aminoglycoside)	Bacterial cell wall (vancomycin) and bacterial 30S ribosome (gentamicin)	Infectious Disease
Azacitidine (AZA)	Azacitidine (AZA)	marketed	DNA methyltransferase inhibitor	DNA methyltransferase (DNMT)	Oncology
GnRH agonist/antagonist	GnRH agonist/antagonist	marketed	GnRH agonist/antagonist	GnRH receptor	Oncology
Revaree Plus	Revaree Plus	marketed
PECS-1	PECS-1	marketed			Other
LAR Lanreotide	LAR Lanreotide	marketed	Somatostatin analog	Somatostatin receptors (SSTR2, SSTR5)	Oncology
Serratus	Serratus	marketed	Non-Standardized Animal Skin Allergenic Extract [EPC]		Other
Maitake	Maitake	marketed			Other

Therapeutic area mix

Oncology · 14
Other · 7
Immunology · 2
Hematology / Surgery / Oncology · 1
Infectious Disease · 1
Infectious Disease / Oncology (supportive care in cancer patients) · 1
Oncology / Infectious Disease Prevention · 1
Anesthesiology · 1
Psychiatry · 1
Dermatology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Hospices Civils de Lyon · 4 shared drug classes
Assistance Publique - Hôpitaux de Paris · 3 shared drug classes
Jiangsu HengRui Medicine Co., Ltd. · 3 shared drug classes
Merck Sharp & Dohme LLC · 3 shared drug classes
Sun Yat-sen University · 3 shared drug classes
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 2 shared drug classes
Celltrion · 2 shared drug classes
Amgen · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Memorial Sloan Kettering Cancer Center:

Cite this brief

Drug Landscape (2026). Memorial Sloan Kettering Cancer Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/memorial-sloan-kettering-cancer-center. Accessed 2026-05-17.